Revvity adds FDA-cleared total testosterone assay to ChLIA menu
Bottom line
Revvity said on May 13, 2026, that the FDA cleared its automated chemiluminescence immunoassay, or ChLIA, for total testosterone, adding it to the company’s existing FDA-cleared assays for free testosterone and sex hormone-binding globulin, or SHBG. The company says that makes its IDS platform the first FDA-cleared ChLIA portfolio to directly measure all three analytes on a single automated system, aimed at workups for testosterone-related disorders, including suspected hypogonadism. Revvity also said the assay runs on its IDS random-access automation platforms and is designed to simplify lab workflow compared with more complex equilibrium dialysis and LC-MS methods. (news.revvity.com)
Why it matters: For veterinary professionals, this is mainly a human diagnostics development, not a veterinary-specific clearance. Still, it’s a useful signal about where endocrine testing is heading: toward more automated, integrated hormone panels with faster turnaround and less technical complexity. That matters because testosterone testing has long faced concerns around assay standardization, accuracy, and workflow burden, especially when compared with reference-style methods such as equilibrium dialysis and mass spectrometry. (news.revvity.com)
What to watch: Watch for whether Revvity publishes more performance data, secures broader lab adoption, or expands the platform’s endocrine menu further in the months ahead. (news.revvity.com)
Key facts
- Company
- Revvity
- FDA clearance date
- May 13, 2026
- Test
- Automated chemiluminescence immunoassay (ChLIA) for total testosterone
- Platform
- IDS random-access automation systems
- Existing cleared assays
- Free testosterone and sex hormone-binding globulin (SHBG)
- Claimed distinction
- First FDA-cleared ChLIA portfolio to directly measure total testosterone, free testosterone, and SHBG on one automated system
- Intended use
- Workups for testosterone-related disorders, including suspected hypogonadism
- Workflow comparison
- Designed to simplify lab workflow versus equilibrium dialysis and LC-MS methods
Revvity has received FDA clearance for its total testosterone automated chemiluminescence immunoassay, giving the company a fuller testosterone-testing menu on its IDS automation platform. Announced May 13, 2026, the clearance adds total testosterone to Revvity’s previously cleared free testosterone and SHBG assays, which the company says creates the only FDA-cleared ChLIA portfolio with direct measurement of all three analytes on one platform. (news.revvity.com)
The move builds on Revvity’s earlier FDA clearance for an automated free testosterone test, announced in January 2025. In that earlier release, the company positioned the assay as a direct-measurement option for conditions including hypogonadism and PCOS, while emphasizing quick turnaround, high throughput, and minimal technician training on its iSYS and i10 instruments. The new total testosterone clearance extends that strategy from a single assay to a more complete endocrinology workflow. (s202.q4cdn.com)
According to Revvity, the newly cleared assay is processed on IDS random-access automation systems and is intended to support first- and second-line diagnostic testing for suspected hypogonadism in men. The company says the expanded portfolio can replace equilibrium dialysis–liquid chromatography/mass spectrometry workflows that require more specialized technology, more manual steps, and complex calculations, while preserving accuracy and reliability. FDA’s 510(k) framework, which applies to many in vitro diagnostic clearances, is designed to determine whether a device is substantially equivalent to an already marketed device. (news.revvity.com)
Independent commentary specific to this clearance appears limited so far, but the broader laboratory medicine context helps explain why the announcement matters. Testosterone testing has been a long-running pain point in endocrinology and lab medicine because assay performance, standardization, and interpretation can vary across methods and laboratories. The Endocrine Society has previously warned that testosterone assays need strong accuracy and precision, and later standardization efforts from endocrine and laboratory groups underscored that inter-assay variation can complicate the biochemical confirmation of hypogonadism. (academic.oup.com)
That context is important when companies pitch automated immunoassays as alternatives to equilibrium dialysis and LC-MS workflows. Reference-style methods remain important because they are often treated as benchmark approaches, especially for free testosterone, but they are operationally demanding and not widely available in routine settings. Revvity’s value proposition is essentially that labs can get a more streamlined, single-platform workflow for total testosterone, free testosterone, and SHBG without having to stitch together multiple methods. That’s an inference based on the company’s product positioning and the longstanding workflow challenges described in the literature. (news.revvity.com)
Why it matters: For veterinary professionals, the direct clinical impact is limited because this is a human IVD clearance, not a veterinary diagnostic authorization. But the development is still relevant as a market and technology signal. Companion animal endocrinology increasingly depends on expectations shaped by human diagnostics, including faster turnaround, higher automation, and more integrated hormone testing. For veterinary reference labs and industry watchers, the bigger takeaway is that endocrine assay developers are still competing on workflow simplification as much as on analytical performance, especially in areas where traditional reference methods are accurate but cumbersome. (news.revvity.com)
It also highlights a familiar tension for diagnostic labs: convenience versus confidence. Automated immunoassays can improve throughput and accessibility, but testosterone measurement has a history of method-specific variability that makes validation, reference ranges, and interpretation especially important. For veterinarians counseling pet parents about hormone testing, that broader lesson carries over even if the specific assay does not: the method behind the number matters. (academic.oup.com)
What to watch: Next, watch for the assay’s 510(k) listing details, any peer-reviewed performance data, and whether major clinical labs adopt the full Revvity testosterone panel as a routine alternative to more complex reference-method workflows. (fda.gov)